WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--June 5, 2006--Merck & Co., Inc. today announced it now anticipates the filing of the New Drug Application to the U.S. Food and Drug Administration for MK-0431A, the Company’s investigational oral medicine combining JANUVIA(TM) (sitagliptin phosphate) with metformin for type 2 diabetes, will occur in 2006 vs. in 2007 as initially anticipated. The Company will provide additional information on JANUVIA and its use with metformin later this week at the annual scientific sessions of the American Diabetes Association in Washington, D.C.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
Forwarding-Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck’s business, particularly those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.
Contact: Merck & Co., Inc. Media: Amy Rose, 908-423-6537 Tracy Ogden, 267-305-0960 Investors: Graeme Bell, 908-423-5185
Source: Merck & Co., Inc.
